Phaseline

Companies › Hrain Biotechnology

Hrain Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Human BCMA Targeted T Cells Injection (BCMA CAR-T)
BCMA-targeted CAR-T cell therapy
BCMAPhase 2Multiple MyelomaJul 2027
Anti-Human CD70 T-Cell Injection
Anti-CD70 CAR-T cell therapy
CD70Phase 1Renal Cell Carcinoma (RCC)Jun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05594797Human BCMA Targeted T Cells Injection (BCMA CAR-T)Phase 2Multiple MyelomaOncologyJul 2027
NCT07647744Anti-Human CD70 T-Cell InjectionPhase 1Renal Cell Carcinoma (RCC)OncologyJun 2029

Targets

BCMA (1) CD70 (1)

Companies with the same targets

Chongqing Precision Biotech iCell Gene Therapeutics AbbVie Allogene Therapeutics Poseida Therapeutics Regeneron Pharmaceuticals Johnson & Johnson (Janssen) AstraZeneca Lakefront Biotherapeutics West Gracell Biotechnologies (Shanghai)

Companies built like this

Marzieh Ebrahimi Beijing Yongtai Ruike Biotechnology Company iCell Gene Therapeutics Hebei Senlang Biotechnology Hangzhou Converd

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.